Overview

Multiple Ascending Dose Study in Healthy Subjects

Status:
Terminated

Trial end date:
2019-06-27

Target enrollment:

Participant gender:

Summary

This will be a Phase 1, randomized, double-blind, single center, placebo-controlled, multiple ascending dose (MAD) study in a maximum of 3 cohorts of 8 healthy male and female subjects each. Subjects in Cohorts 1, 2 and 3 will receive ascending multiple IV doses of NPT189 or matching placebo.

Phase:

Phase 1

Details

Lead Sponsor:

Proclara Biosciences, Inc.

Treatments:

Antibodies
Immunoglobulin G
Immunoglobulins